CLAIMS

1. Use of fitusiran in the manufacture of a medicament for improving the quality of life of a hemophilia patient, wherein the medicament comprises about 50 mg of fitusiran, wherein the medicament is suitable for subcutaneous administration to a hemophilia patient in need thereof about once a month or about once every two months, wherein the improvement is a clinically meaningful improvement from baseline in the health-related quality of life (HRQoL) of the patient.

2. The use according to claim 1, wherein the clinically meaningful improvement is in the physical functioning of the patient.

3. The use according to claim 2, wherein the physical functioning includes pain in movement and/or difficulty walking far.

4. The use according to claim 2, wherein the physical functioning is determined by the Physical Health score and/or the Total Score of the Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL).

5. The use according to any one of claims 1-4, wherein the patient is an adult or adolescent patient twelve years or older.

6. The use according to any one of claims 1-5, wherein the patient has hemophilia A.

7. The use according to claim 6, wherein the patient has been treated with factor VIII or a bypassing agent (BPA).

8. The use according to claim 7, wherein the patient is a patient with factor VIII inhibitors, optionally wherein the level of factor VIII inhibitors is more than 0.6 BU/mL as determined by Bethesda inhibitor assay.

9. The use according to claim 6 or 7, wherein the patient is a patient without factor VIII inhibitors.

10. The use according to any one of claims 1-5, wherein the patient has hemophilia B.

11. The use according to claim 10, wherein the patient has been treated with factor IX or a BPA.

12. The use according to claim 11, wherein the patient is a patient with factor IX inhibitors, optionally wherein the level of factor IX inhibitors is more than 0.6 BU/mL as determined by Bethesda inhibitor assay.

13. The use according to claim 10 or 11, wherein the patient is a patient without factor IX inhibitors.

14. The use according to any one of claims 7-9 or 11-13, wherein the patient has been treated with a BPA, wherein the BPA is activated prothrombin complex concentrates (aPCC) and/or recombinant activated Factor VII (rFVIIa).

15. The use according to any one of claims 1-14, wherein the medicament comprises fitusiran at a concentration of 50-200 mg/mL, or optionally at a concentration of about 100 mg/mL, in a phosphate-buffered saline (pH 7).

16. The use according to any one of claims 1-15, wherein the medicament is suitable for administration to the patient about once a month.

17. The use according to any one of claims 1-15, wherein the medicament is suitable for administration to the patient about once every two months.

18. The use according to any one of claims 1-17, wherein the use of the medicament improves joint function in the patient.

19. The use according to any one of claims 1-18, wherein the use of the medicament improves a joint symptom in the patient, wherein the joint symptom is selected from joint swelling, painful movement, and joint pain.